Jacobson Pharma Corp Ltd (HKEX: 02633) has announced its financial results for the fiscal year ended March 31, 2026. The group reported revenue of HK$1.569 billion, representing a slight decrease of 0.47% compared to the previous year.

The profit attributable to the company's equity holders was HK$302 million, marking a modest increase of 0.26% year-on-year. Earnings per share stood at 15.1 HK cents, and the board has proposed a final dividend of 4.75 HK cents per share.

Despite the marginal decline in annual revenue, the company achieved growth in profit attributable to equity holders, demonstrating the robust resilience of its core operations. This performance was driven by stringent cost control measures, continuous improvements in operational efficiency, and a well-balanced, diversified business portfolio.

The expansion of the chronic disease and specialty drug portfolio, alongside contributions from newly launched products and the introduction of licensed pharmaceuticals and therapies, has further strengthened the sustainability and diversity of the company's earnings base.

Bolstered by a solid balance sheet, strong cash flow generation, and a prudent capital-to-debt ratio, the company is well-positioned to pursue strategic investments while maintaining financial flexibility to capitalize on future growth opportunities.